Evidence map›Paper›PMID 27829451›Full record

ArticleMicrobial cell factories2016

Elucidation of the glycosylation steps during biosynthesis of antitumor macrolides PM100117 and PM100118 and engineering for novel derivatives.

Raúl García Salcedo, Carlos Olano, Rogelio Fernández, Alfredo F Braña, Carmen Méndez, Fernando de la Calle, José A Salas

Abstract read
In one paragraph

Article in Microbial cell factories, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Rethinking Biosynthesis of Aclacinomycin A.Molecules (Basel, Switzerland) · 2023
    Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Raúl García SalcedoDepartamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias (I.U.O.P.A), Universidad de Oviedo, Asturias, 33006, Oviedo, Spain.
Carlos OlanoDepartamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias (I.U.O.P.A), Universidad de Oviedo, Asturias, 33006, Oviedo, Spain.
Rogelio FernándezDrug Discovery Area, PharmaMar S.A., Avda. de los Reyes, Colmenar Viejo, 128770, Madrid, Spain.
Alfredo F BrañaDepartamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias (I.U.O.P.A), Universidad de Oviedo, Asturias, 33006, Oviedo, Spain.
Carmen MéndezDepartamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias (I.U.O.P.A), Universidad de Oviedo, Asturias, 33006, Oviedo, Spain.
Fernando de la CalleDrug Discovery Area, PharmaMar S.A., Avda. de los Reyes, Colmenar Viejo, 128770, Madrid, Spain.
José A SalasDepartamento de Biología Funcional e Instituto Universitario de Oncología del Principado de Asturias (I.U.O.P.A), Universidad de Oviedo, Asturias, 33006, Oviedo, Spain. jasalas@uniovi.es.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAntitumor compounds PM100117 and PM100118 are glycosylated polyketides derived from the marine actinobacteria Streptomyces caniferus GUA-06-05-006A. The organization and characterization of the PM100117/18 biosynthesis gene cluster has been recently reported.

resultsBased on the preceding information and new genetic engineering data, we have outlined the pathway by which PM100117/18 are glycosylated. Furthermore, these genetic engineering experiments have allowed the generation of novel PM100117/18 analogues. Deletion of putative glycosyltranferase genes and additional genes presumably involved in late biosynthesis steps of the three 2,6-dideoxysugars appended to the PM100117/18 polyketide skeleton, resulted in the generation of a series of intermediates and novel derivatives.

conclusionsIsolation and identification of the novel compounds constitutes an important contribution to our knowledge on PM100117/18 glycosylation, and set the basis for further characterization of specific enzymatic reactions, additional genetic engineering and combinatorial biosynthesis approaches.

Indexed as

A549 CellsAntineoplastic AgentsCell Line, TumorDrug Screening Assays, AntitumorGene DeletionGenetic EngineeringGlycosylationGlycosyltransferasesHT29 CellsHumansMacrolidesStreptomycesAntineoplastic AgentsGlycosyltransferasesMacrolidesPM100117PM100118AntitumorDeoxysugarGlycosyltranferaseStructural analogue

Identifiers

PMID27829451
PMCPMC5103430

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.